Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
Launched by EXELIXIS · Sep 20, 2005
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective
- • Eastern Cooperative Oncology Group (ECOG) performance status \</= 2
- • Life expectancy greater than 3 months
- • Adequate organ and marrow function
- • Written informed consent
- • Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study
- • In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST
- Exclusion Criteria:
- • Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184
- • Administration of an investigational drug within 30 days of the first dose of XL184
- • Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment
- • Known brain metastases
- • Uncontrolled intercurrent illness
- • Pregnancy or breastfeeding
- • Known HIV positive
- • Known allergy or hypersensitivity to any of the components of the XL184 formulation
About Exelixis
Exelixis, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. With a commitment to advancing precision medicine, Exelixis leverages its expertise in small molecule drug discovery to address unmet medical needs in oncology. The company's robust pipeline includes a range of investigational compounds targeting various cancer types, supported by rigorous clinical trials that aim to improve patient outcomes. Through collaboration and a patient-centric approach, Exelixis strives to deliver transformative therapies that enhance the quality of life for those affected by cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Chicago, Illinois, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Baltimore, Maryland, United States
Houston, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials